EUVIMEDObjevte EUVIMED
Open access

Interpretable dynamic quantitative vascular morphometry features using SHAP for anti-angiogenic therapy response prediction

Kui Hu iD, Qian Cai iD, Jia Xu iD, Shuangquan Ai iD, Wuling Ou iD, Yulin Liu iD

Science Advances · 2026-07-24 · 12 (30)

DOI: 10.1126/sciadv.aeb3543 ↗

At a glance

Journal article in Science Advances, published on 2026-07-24. Written by Kui Hu and 5 co-authors. Institution: Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Major MEDLINE topics: Angiogenesis Inhibitors, Lung Neoplasms, Neovascularization, Pathologic. 30 references. The full text is freely available in PubMed Central. Funded by: Hubei Provincial Key Technology Foundation of China, Chutian Talents of Hubei, Talent Project of Hubei Cancer Hospital.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Anti-angiogenic therapy benefits vary, with response rates of 40 to 70%, highlighting the need for early biomarkers to identify responders. We developed an automated machine learning framework that uses delta quantitative vascular morphometry features from standard contrast-enhanced CT to evaluate treatment response. This workflow combines automated tumor and vessel segmentation with feature extraction from routine scans for clinical use. Shapley additive explanations (SHAP)–based attributions identify key vascular and clinical features, providing meaningful, imaging-visible evidence aligned with therapy targets beyond traditional radiomics. Using baseline and follow-up CTs from 163 patients with lung cancer, we built three models using fivefold cross-validation, with the delta-merge model achieving high accuracy (area under the receiver operating characteristic curve = 0.842 internally, 0.806 externally). SHAP analysis uncovered an “arterial-dominant, venous-adaptive” pattern, where arterial involvement and venous recovery distinguish responders. This automated workflow and visualization support early, imaging-based response assessment and personalized treatment.

Subjects

MeSH terms (MEDLINE)

Angiogenesis InhibitorsLung NeoplasmsNeovascularization, PathologicHumansRadiomicsTomography, X-Ray ComputedMachine LearningROC CurveTreatment OutcomeFemale

Substances

Angiogenesis Inhibitors

Authors and institutions

  • Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Wuhan 430074, China.
  • Thoracic Inner Department I, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • College of Biomedical Engineering, South-Central Minzu University, Wuhan, Hubei, China.

ORCID profiles: Kui Hu, Qian Cai, Jia Xu, Shuangquan Ai, Wuling Ou, Yulin Liu

Funding

  • Hubei Provincial Key Technology Foundation of China
  • Chutian Talents of Hubei
  • Talent Project of Hubei Cancer Hospital

Cite

APA

Hu, K., Cai, Q., Xu, J., Ai, S., Ou, W., & Liu, Y. (2026). Interpretable dynamic quantitative vascular morphometry features using SHAP for anti-angiogenic therapy response prediction. Science Advances, 12(30). https://doi.org/10.1126/sciadv.aeb3543

Vancouver

Hu K, Cai Q, Xu J, Ai S, Ou W, Liu Y. Interpretable dynamic quantitative vascular morphometry features using SHAP for anti-angiogenic therapy response prediction. Science Advances. 2026;12(30). doi:10.1126/sciadv.aeb3543

BibTeX
@article{Hu2026,
  author = {Hu, Kui and Cai, Qian and Xu, Jia and Ai, Shuangquan and Ou, Wuling and Liu, Yulin},
  title = {Interpretable dynamic quantitative vascular morphometry features using SHAP for anti-angiogenic therapy response prediction},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {30},
  doi = {10.1126/sciadv.aeb3543}
}
Start for free →